Tenaya Therapeutics: Clinical Trials

3 recruiting, 1 active not recruiting. 2 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Recruiting 2
Phase 2	1	Recruiting 1

Follow Tenaya Therapeutics: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC TN-401 - Arrhythmogenic Right Ventricular Cardiomyopathy	Phase 1	Recruiting	Tenaya Therapeutics	15	2024-03-26	2025-02-06
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM TN-201 - Hypertrophic Cardiomyopathy	Phase 1 / Phase 2	Recruiting	Tenaya Therapeutics	30	2023-08-10	2026-03-19
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Arrhythmogenic Right Ventricular Cardiomyopathy		Recruiting	Tenaya Therapeutics	200	2023-01-31	2024-11-01
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy Cardiomyopathy		Active not recruiting	Tenaya Therapeutics	200	2021-11-01	2026-09-02

Conditions studied

Arrhythmogenic Right Ventricular Dysplasia (2)  ·  Cardiomyopathy, Hypertrophic (2)  ·  Heart Failure (2)  ·  Cardiomyopathies (1)  ·  Cardiomyopathy, Dilated (1)  ·  Cardiomyopathy, Hypertrophic, Familial (1)  ·  Cardiomyopathy, Restrictive (1)

Countries

United States (4)  ·  United Kingdom (2)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)  ·  Sweden (1)

Results publications

PMID 39302117